financetom
Business
financetom
/
Business
/
--Albemarle Keeps Quarterly Dividend at $0.405 a Share, Payable Jan. 2, 2025, to Shareholders of Record Dec. 13, 2024
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Albemarle Keeps Quarterly Dividend at $0.405 a Share, Payable Jan. 2, 2025, to Shareholders of Record Dec. 13, 2024
Nov 3, 2024 1:15 PM

05:50 PM EDT, 10/28/2024 (MT Newswires) --

Price: 97.93, Change: -0.21, Percent Change: -0.21

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Mar 19, 2026
BOSTON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the Code) 1. KEY INFORMATION (a) Full name of discloser: Weiss Asset Management LP (Investment Manager of Brookdale International Partners, L.P. and Brookdale Global Opportunity Fund) (b) Owner or controller of interests...
Form 8.3
Form 8.3
Mar 19, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Pfizer Combo Therapy Scores Major Win In Prostate Cancer Trial
Pfizer Combo Therapy Scores Major Win In Prostate Cancer Trial
Mar 19, 2026
Pfizer Inc. ( PFE ) shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic castration-sensitive prostate cancer (mCSPC). Pfizer Talzenna Plus Xtandi Hit Primary Goal On Thursday, the U.S. drug giant reported topline data from the TALAPRO-3 Phase 3 study of Talzenna (talazoparib) in combination with...
Update: Market Chatter: Goldman, JPMorgan Offering Hedge Funds Bets Shorting Private Credit
Update: Market Chatter: Goldman, JPMorgan Offering Hedge Funds Bets Shorting Private Credit
Mar 19, 2026
11:22 AM EDT, 03/19/2026 (MT Newswires) -- (Update with JPMorgan Chase's ( JPM ) response to a request for comment from MT Newswires.) Goldman Sachs Group ( GS ) and JPMorgan Chase ( JPM ) are among a number of investment banks offering their hedge fund clients ways to short the $1.8 trillion private credit market, Bloomberg reported Thursday, citing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved